Dr. Yarchoan has played a major role in developing the first successful drugs to treat HIV infection. More recently, his research is focused on the study of and development of treatment for HIV-associated malignancies, with a focus on those caused by Kaposi sarcoma-associated herpesvirus (KSHV). As Chief, Dr. Yarchoan oversees the Branch’s clinical/translational research program, which encompasses the development of novel therapies for HIV infection, the study of the viral causes of HIV-associated malignancies, and the development of novel therapies for HIV-associated malignancies.